Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy
Open Access
- 1 January 2010
- journal article
- review article
- Published by E-MED LTD in Cancer Imaging
- Vol. 10 (1A), 83-91
- https://doi.org/10.1102/1470-7330.2010.9007
Abstract
Imaging of neuroendocrine tumours (NET) poses significant challenges because of the heterogeneous biology of the tumours that are represented by this class of neoplasia. NET can range from benign lesions to highly aggressive cancers. Structural imaging ...This publication has 36 references indexed in Scilit:
- 177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotideEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- Endocrine Tumors of the Gut and Pancreas Tumor Biology and ClassificationNeuroendocrinology, 2004
- Clinical value of somatostatin receptor imaging in patients with suspected head and neck paragangliomasEuropean Journal of Nuclear Medicine and Molecular Imaging, 2002
- 111In-pentetreotide scintigraphy is superior to 123I-MIBG scintigraphy in the diagnosis and location of chemodectomaNuclear Medicine Communications, 1998
- Positron emission tomography with 5-hydroxytryprophan in neuroendocrine tumors.Journal of Clinical Oncology, 1998
- Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma.1995
- Somatostatin Receptor Scintigraphy in Carcinoids, Gastrinomas and Cushing’s SyndromeDigestion, 1994
- Octreotide scintigraphy for the detection of paragangliomas.1993
- 111In-octreotide scintigraphy in oncologyMetabolism, 1992
- Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasmsCancer, 1991